StockDuty ← Dashboard Nov 04, 2026 12:31 AM ET
SignalKorea

Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs

Boehringer seeks Korean biotech partnerships for drug breakthroughs.

What happened: Boehringer Ingelheim CEO Shashank Deshpande said the company aims to deepen partnerships with Korean biotech firms, citing the AimedBio antibody-drug conjugate deal as a key example. Key numbers: AimedBio license deal worth up to $991 million, signed October last year. The molecule entered Phase 1 trials with the first patient enrolled. Why it matters: Deshpande said Korea is no longer viewed only as a sales and marketing market, and he expects such arrangements to grow as the country's biotech sector expands and contributes to global drug development.
Boehringer Ingelheim CEO Shashank Deshpande said the company aims to deepen partnerships with Korean biotech firms, citing the AimedBio antibody-drug conjugate deal as a key example.
Deshpande said Korea is no longer viewed only as a sales and marketing market, and he expects such arrangements to grow as the country's biotech sector expands and contributes to global drug development.
Sources